Kumar Yogesh, Sharma Pranav, Bhatt Neeraj, Hooda Kusum
Diagnostic Radiology, Yale New Haven Health System at Bridgeport Hospital, Bridgeport, USA. E-mail :
Asian Pac J Cancer Prev. 2016;17(2):473-8. doi: 10.7314/apjcp.2016.17.2.473.
Hepatocellular cancer is a very common cause of cancer related deaths worldwide. Only 30-40% of patients present with early-stage disease open to curative treatments, such as resection or transplantation, while others can only undergo local therapies or palliative care. Various trans-arterial approaches have been used for treatment of hepatocellular carcinoma in patients who need a down-staging to liver transplantation, and who are not candidates for transplantation or radiofrequency ablation. Transarterial chemoembolization (TACE), transarterial embolization (TAE), drug-eluting beads, and radioembolization have been used for locoregional control, and have been shown to prolong the overall survival when compared with supportive care. In this review, we discuss patient selection, pre- and post-procedure imaging, techniques, safety, and clinical outcomes related to these therapies. Newer advances with future directions in various fields related to trans-arterial therapies are also discussed.
肝细胞癌是全球癌症相关死亡的常见原因。只有30%-40%的患者表现为可接受根治性治疗(如切除或移植)的早期疾病,而其他患者只能接受局部治疗或姑息治疗。对于那些需要降期以进行肝移植、不适合移植或射频消融的肝细胞癌患者,已采用各种经动脉方法进行治疗。经动脉化疗栓塞术(TACE)、经动脉栓塞术(TAE)、载药微球和放射性栓塞已用于局部控制,并且与支持治疗相比已显示可延长总生存期。在本综述中,我们讨论了与这些治疗相关的患者选择、术前和术后成像、技术、安全性及临床结果。还讨论了经动脉治疗相关各个领域的最新进展及未来方向。